



If the following information is not complete, correct, or legible, the SA process can be delayed.

Please use one form per member.

**MEMBER INFORMATION**

Last Name:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

First Name:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

Medicaid ID Number:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

Date of Birth:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

Gender:  Male  Female

Member Age: \_\_\_\_\_

**PRESCRIBER INFORMATION**

Last Name:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

First Name:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

NPI Number:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

Phone Number:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

Fax Number:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

Prescriber Specialty: Indicate the prescriber's specialty or in consultation with:

Gastroenterologist  Hepatologist  Transplant Specialist  Infectious Disease

Other: \_\_\_\_\_

**DRUG INFORMATION**

Drug Name/Form: \_\_\_\_\_

Strength: \_\_\_\_\_

Dosing Frequency: \_\_\_\_\_

Length of Therapy: \_\_\_\_\_

Quantity per Day: \_\_\_\_\_

(Form continued on next page.)

Member's Last Name:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

Member's First Name:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

**DIAGNOSIS**

- Chronic Hepatitis C     
  Compensated cirrhosis     
  Hepatocellular carcinoma  
 Decompensated cirrhosis (Child-Pugh score class B or C)     
  Status post-liver transplant

**HCV Genotype:**

- 1a with polymorphism (*submit test results*)     
  1a without polymorphism (*submit test results*)  
 1b     
  2     
  3     
  4     
  5     
  6

**Choose One:**     Treatment initiation     Continuation of therapy, current week: \_\_\_\_\_

**ADHERENCE**

1. Has the prescriber assessed the member for adherence with medical and pharmacological treatment?  
 Yes     No

**SUBSTANCE USE DISORDER SCREENING**

2. Has the prescriber evaluated the member for current substance use disorder including alcohol use disorder?
- Members identified with a substance use disorder should be referred for treatment.
  - **Members cannot be denied Hepatitis C treatment for sole reason of substance use.**
  - Testing for illicit drug and/or alcohol use is not required.
- Yes     No

**OTHER CO-MORBID CONDITION(S)**

3. Decompensated cirrhosis (Child-Pugh score greater than 6 [class B or C])?  
 Yes     No
4. Hx severe renal impairment (eGFR <30 mL/min/1.73m<sup>2</sup>) or end stage renal disease requiring hemodialysis?  
 Yes     No
5. If Yes to any, provide details: \_\_\_\_\_  
 \_\_\_\_\_  
 \_\_\_\_\_

(Form continued on next page.)

Member's Last Name:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

Member's First Name:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

**LAB VALUES**

- 6. Original Baseline: \_\_\_\_\_ HCV RNA value: \_\_\_\_\_ Date Drawn: \_\_\_\_\_
- 7. Current Baseline: \_\_\_\_\_ HCV RNA value: \_\_\_\_\_ Date Drawn: \_\_\_\_\_  
(within past 4 weeks)
- 8. Tx Week 4: \_\_\_\_\_ HCV RNA value: \_\_\_\_\_ Date Drawn: \_\_\_\_\_
- 9. Tx Week Other: \_\_\_\_\_ HCV RNA value: \_\_\_\_\_ Date Drawn: \_\_\_\_\_

If HCV RNA is detectable at week 4 of treatment, repeat quantitative HCV RNA viral load testing is recommended after 2 additional weeks of treatment (treatment week 6). If quantitative HCV viral load has increased by greater than 10-fold (>1 log<sub>10</sub> IU/mL) on repeat testing at week 6 (or thereafter), then discontinuation of HCV treatment is recommended.

**PREVIOUS HEPATITIS C TREATMENTS**

- Treatment naïve
- Treatment experienced with (check all that apply):
  - Daklinza™ (daclatasvir)                       Epclusa® (sofosbuvir/velpatasvir)
  - Harvoni® (ledipasvir-sofosbuvir)             Incivek® (telaprevir)
  - Interferon     ledipasvir-sofosbuvir
  - Olysio™ (simeprevir)                               peginterferon
  - ribavirin     sofosbuvir/velpatasvir
  - Sovaldi® (sofosbuvir)                               Technivie® (ombitasvir/paritaprevir/ritonavir)
  - Viekira Pak™ (ombitasvir/paritaprevir/ritonavir) with dasabuvir
  - Viekira XR™ (ombitasvir/paritaprevir/ritonavir; dasabuvir)
  - Zepatier™ (elbasvir and grazoprevir)

Document dates received: \_\_\_\_\_

**Prescriber Signature (Required)**

**Date**

By signature, the Physician confirms the above information is accurate and verifiable by member records.

**Please include ALL requested information; Incomplete forms will delay the SA process.**

Submission of documentation does NOT guarantee coverage by the Department of Medical Assistance Services.

The completed form may be: **FAXED TO 800-932-6651**, phoned to 800-932-6648, or mailed to:

Magellan Medicaid Administration / ATTN: MAP  
11013 W. Broad Street, Glen Allen, VA 23060

Virginia Medicaid Pharmacy Services Portal: <http://www.virginiamedicaidpharmacyservices.com>

© 2017–2019, Magellan Health, Inc. All rights reserved.      Revised: 05/23/2019 | Effective: 07/01/2019